Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Sanofi Pasteur Commends Saudi Arabia for Being Declared Polio-Free.
- RIYADH, Saudi Arabia, March 4 /PRNewswire/ -- - Sanofi Pasteur Recognized as a key Contributor to Polio Eradication Efforts Sanofi pasteur (NYSE: SNY), the vaccines business of the sanofi-aventis Group, commends the Kingdom of Saudi Arabia for being declared a...
- Research articles 2007-03-04
- Sanofi fighting generic drugs tooth and nail in US courts
- PARIS AFP — The French pharmaceuticals group Sanofi-Aventis is turning to vigorous legal action to protect its best-selling drugs in the United States from cheaper generic competition. "We are sure of our patents," a spokesman for Sanofi-Aventis, the world's third largest drug group, said Wednesday. Sanofi announced it...
- Research articles 2006-08-09
- Sanofi slumps on US criminal probe into generics deal
- PARIS AFP — Shares in Sanofi-Aventis fell sharply on news that a deal it struck to keep a cheaper generic version of its blockbuster drug Plavix off the market was the subject of a US criminal investigation. Shares in Sanofi, a heavyweight on the Paris market, plunged by 3.88...
- Research articles 2006-07-27
- Sanofi-Aventis posts profit gain; share price tumbles on pipeline news
- PARIS AFP — Pharmaceutical group Sanofi-Aventis reported a 26 percent rise in second-quarter net profit from a year ago but its share price fell sharply on a mixed picture for new product prospects. The group posted second-quarter net profit of 1.553 billion euros (1.9 billion dollars), beating analysts' estimates...
- Research articles 2005-08-31
- US authorities clear Sanofi takeover offer for Aventis
- WASHINGTON AFP ? US regulatory authorities conditionally agreed to accept the pending merger of French-German pharmaceutical group Aventis and its smaller French rival Sanofi-Synthelabo into the world's third-largest pharmaceutical group. The Federal Trade Commission agreed to the merger on the condition that the two companies give up key drug...
- Research articles 2004-07-29
- Sanofi says US FTC wants more information on Aventis takeover
- PARIS AFP ? French pharmaceutical group Sanofi-Synthelabo said the US Federal Trade Commission had asked for more information on Sanofi's takeover bid for French-German rival Aventis, to complete an FTC investigation. The FTC's decision would not delay the completion of the offer, expected before the end of the second...
- Research articles 2004-05-05
- Sanofi board discussing details of Aventis bid: source
- PARIS AFP ? The board of French pharmaceutical group Sanofi-Synthelabo was finalising a hostile bid for Franco-German rival Aventis which it was expected to launch on Monday, an informed source told AFP. "The board members are discussing the details of the offer," the source said. The takeover bid...
- Research articles 2004-01-25
- Drug deals deliver.
- Investment advisers are profiting from the reorganizations occurring in the pharmaceutical industry in response to increased demand for cheaper drugs and lower health care costs. Most of the international mergers and acquisitions (M&A) for the first nine months of 1994 have a predominantly transatlantic theme, mirroring the strength of US...
- Research articles 1994-11-01
- Sanofi's Multaq Unlikely to Be a Blockbuster, Says Analyst
- Before Sanofi-Aventis launched its heart drug Multaq, some analysts estimated revenues would top €3 billion. But 10 weeks into the launch, Multaq looks like a much more modest affair, according to a note to investors from Jefferies International. by Jim Edwards
- Blog posts 2009-10-06
- Cynicism Winning Debate Over Sanofi's Lantus and Cancer
- In the flap over whether Sanofi-Aventis' Lantus diabetes drug has an association with cancer, cynicism seems to be winning. Sanofi's stock see graph seems not to have recovered from reports that Lantus was linked to cancer, even though Sanofi obtained an approval for a new heart drug, Multaq. Meanwhile, Sanofi's...
- Blog posts 2009-07-07
- Sanofi's Lantus Cancer Scare Shows How Enormous Power Lies With Few Experts
- The cancer scare over Sanofi-Aventis' Lantus shows just how much power over a company's drug sales -- and its stock -- are now concentrated in the hands of a tiny number of experts. Sanofi CEO Chris Viehbacher came out of his corner swinging Monday, saying an article in Study of...
- Blog posts 2009-06-29
- Sanofi Eats Merck's Vaccine Business for Lunch; Hopes Pinned on "Gardasil for Boys"
- Merck should have been cheered by the news that the CDC plans to reinstate booster shots of meningitis vaccine for kids because the vaccine supply has come back online. The company, after all, has a large vaccine division. But it is just salt in Merck's wounds. by Jim Edwards
- Blog posts 2009-06-26
- Sanofi Gets Jennifer Lopez to Hawk Pentacell Pertussis Vaccine
- Sanofi Pasteur, the vaccines unit of Sanofi-Aventis, has persuaded singer Jennifer Lopez to become its joint spokesperson with the March of Dimes' "the Sounds of Pertussis," campaign. (There's even a video, in which Lopez looks strangely like Law & Order's Mariska Hargitay.) The effort is to persuade...
- Blog posts 2009-04-23
- Sanofi, Sepracor Keep Local Politicians in Thrall Over Taxes
- Two separate moves, by Sanofi-Aventis and Sepracor, illustrate the power that drug companies can have over the taxes of towns they base their headquarters in. Sanofi backed out of a deal in Pennsylvania that would have saved it 10 years of taxes in order to cut its...
- Blog posts 2009-03-30
- Sanofi CEO Viehbacher Wants More Cuts; Drug Reps' Necks on the Block
- Sanofi-Aventis's Q4 earnings call tomorrow could set the stage for a dramatic few days at the company, according to Bloomberg, as CEO Chris Viehbacher told analysts and his staff that Sanofi needs to cut operating costs and possibly buy a small or midsize firm. Viehbacher wants to get $1.3 billion...
- Blog posts 2009-02-10
- Shire's Big Gamble on ADHD Drug Vyvanse
- One of the recent unheralded successes of the drug world was Shire Pharmaceuticals' launch of Vyvanse, a new, long-acting treatment for attention deficit and hyperactivity disorder. The fact that so little attention has been paid to Vyvanse is a shame because the take-up of this drug has been impressive --...
- Blog posts 2008-09-04
- Why Can't Sanofi Get That Zentiva Deal Done?
- The M&A chess match going on between Sanofi-Aventis and Zentiva, a Czech Republic-based generic drug maker, is fascinating because it seems that the tiny Czech company is the one in a position of strength. Sanofi's bid was rejected by Zentiva on Wednesday. At first glance, it appears...
- Blog posts 2008-09-05
- Sanofi Joins Pfizer in Drug-Based Video Game Business
- Sanofi-Aventis has become the latest drug company to get into the online video game business. This time, it's for its ubiquitous sleeping pill, Ambien CR. The game is called "Silence Your Rooster." The game is part of Sanofi's ad campaign for Ambien, which the Wall Street Journal...
- Blog posts 2008-09-25
- Should Sanofi-Aventis Buy Bristol Myers-Squibb?
- Bristol-Myers Squibb CEO James Cornelius said in a recent earnings call that due to its healthy cash position it may be on the prowl for biotech acquisitions. That's ironic because it is looking more like BMS itself could be the company to be acquired, possibly by Sanofi-Aventis. ...
- Blog posts 2008-10-27
- Solvay, Pfizer, Sanofi Join Merck in Abandoning Obesity Drugs
- For those of you hoping that America’s obesity crisis could be solved with a pill, think again. Pfizer announced late Wednesday that it is scrapping its anti-fat drug, the as-yet unnamed “CP-945,598,†for essentially political reasons. Sanofi-Aventis today also announced that it was ending its trials on Acomplia/Zimulti, an obesity...
- Blog posts 2008-11-05
- << Previous
- page 1 of 2
- Next >>
Refining Tags
- Jim Edwards (17 results)
- Finance (13 results)
- Investment (6 results)
- Sales (6 results)
- Pfizer Inc. (6 results)
- Vaccine (5 results)
- Business Operations (5 results)
- Healthcare (5 results)
- Sanofi-Aventis (4 results)
- Sales Strategy (4 results)
- Agence France-Presse (4 results)
- Operational Accounting (3 results)
- Taxes (3 results)
- Free Trade (3 results)
- Financial Planning (3 results)
- Aventis (3 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
